Public Funding for Entia Ltd

no public description

Entia in partnership with the NHS has developed a new approach to managing chronic kidney disease. This project seeks to ensure that the solution developed addresses the needs of NHS trusts and renal centres across the UK.

"Entia, Hull University Teaching Hospitals NHS Trust and the Yorkshire & Humber Academic Health Science Network are developing a new approach to the management of patients with anaemia of chronic kidney disease. The project encompasses the late stage development of an anaemia management solution that will be co-designed and evaluated with patients and healthcare practitioners. The outcome of this project has the potential to reduce hospital appointments, improve treatment compliance, ensure fewer adverse events and enable more effective utilisation of costly medications."

"50% of people are expected to get cancer at some point in their life. Even with new therapies, many patients will experience unwanted side effects from their treatment that may range from minor psychological issues through to life threatening infections. With cancer patients spending a significant amount of time outside of healthcare facilities, it becomes hard to identify early changes that may lead to such complications. This project shall be the final stage of development for a new home monitoring technology that can reduce unnecessary hospital visits for patients, improve the management of side effects, enhance quality of life and reduce the likelihood of life-threatening adverse events occurring. This platform will operate by allowing recipients of systemic cancer therapy to monitor their blood counts and symptoms within their home whilst sharing that information with their nurses and doctors through a real-time connection that is integrated directly with their care provider. Earlier development work has been undertaken with patients, carers, nurses and clinicians using human centered design processes to ensure that the technology is easy to use and solves genuine problems for people receiving systemic cancer therapy. This project brings together two of the UK's leading hospital trusts, The Royal Marsden NHS Foundation Trust and The Christie NHS Foundation Trust alongside The University of Manchester, Imperial College Health Partners, Entia and iQ Healthtech to ensure this innovation can be rapidly adopted across healthcare."

Over 3 million people suffer from iron-deficiency anaemia (IDA), a condition that can cause exhaustion and impair cognitive function. In a collaborative project, Eva Diagnostics is working alongside NIHR Diagnostics Evidence Cooperative London and the Department of Primary Care and Public Health, Imperial College London to undertake an early-stage design-led project to explore innovative new concepts to empower individuals to better manage their IDA.

For many individuals with cancer, chemotherapy forms a key aspect of treatment. Across the various types of chemotherapy, the majority carry significant side effects that often include the reduction of blood cell counts. The lowering of blood cell counts exposes individuals to higher risk of adverse events such as infection. Low blood counts are also the major cause of delayed treatment or reduced treatment dosage. Such issues can significantly impact the chance of successful treatment, as well as incur greater cost to healthcare systems. Through new analytical technology, this project is seeking to develop a smart handheld technology capable of monitoring blood counts from a single drop of blood. Through home use, our technical solution can optimise treatment delivery, ensure that clinical pathways are closely built around the individual's needs and significantly reduce healthcare expenditure.

Eva Diagnostics is a medical technology and design company that is developing handheld diagnostic systems for the haematology sector. Building upon our existing platform technology, we are exploring the feasibility of a handheld diagnostic system capable of performing haematocrit, haemoglobin, white blood cell count, and platelet count from a single drop of blood.

Eva Diagnostics is a medical design and engineering company commercialising technologies to improve the lives of anaemia sufferers across the globe. We have recently designed a new analysis technology that will lead to a low cost handheld device capable of diagnosing both the presence and type of anaemia. This device shall uniquely provide enough information from a simple finger prick test to assist clinicians in diagnosing the cause of anaemia and subsequently enable sufferers to receive patient-tailored treatments. Our primary market focus is in emerging markets and newly industrialised nations, principally within Africa and Asia.